GB201910794D0 - Vaccine - Google Patents

Vaccine

Info

Publication number
GB201910794D0
GB201910794D0 GBGB1910794.5A GB201910794A GB201910794D0 GB 201910794 D0 GB201910794 D0 GB 201910794D0 GB 201910794 A GB201910794 A GB 201910794A GB 201910794 D0 GB201910794 D0 GB 201910794D0
Authority
GB
United Kingdom
Prior art keywords
vaccine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1910794.5A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pirbright Institute
Original Assignee
Pirbright Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pirbright Institute filed Critical Pirbright Institute
Priority to GBGB1910794.5A priority Critical patent/GB201910794D0/en
Publication of GB201910794D0 publication Critical patent/GB201910794D0/en
Priority to CN202080062696.4A priority patent/CN114375199A/zh
Priority to AU2020322191A priority patent/AU2020322191A1/en
Priority to KR1020227006051A priority patent/KR20220041144A/ko
Priority to PH1/2022/550063A priority patent/PH12022550063A1/en
Priority to US17/628,286 priority patent/US20220273788A1/en
Priority to JP2022505456A priority patent/JP2022542174A/ja
Priority to PCT/GB2020/051808 priority patent/WO2021019232A1/en
Priority to TW109125471A priority patent/TW202118771A/zh
Priority to MX2022001028A priority patent/MX2022001028A/es
Priority to BR112022000865A priority patent/BR112022000865A2/pt
Priority to EP20751252.6A priority patent/EP4003412A1/en
Priority to CA3148586A priority patent/CA3148586A1/en
Priority to CL2022000161A priority patent/CL2022000161A1/es
Priority to CONC2022/0001782A priority patent/CO2022001782A2/es
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/12011—Asfarviridae
    • C12N2710/12022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/12011—Asfarviridae
    • C12N2710/12034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
GBGB1910794.5A 2019-07-29 2019-07-29 Vaccine Ceased GB201910794D0 (en)

Priority Applications (15)

Application Number Priority Date Filing Date Title
GBGB1910794.5A GB201910794D0 (en) 2019-07-29 2019-07-29 Vaccine
CA3148586A CA3148586A1 (en) 2019-07-29 2020-07-28 African swine fever vaccine
JP2022505456A JP2022542174A (ja) 2019-07-29 2020-07-28 アフリカ豚熱ワクチン
TW109125471A TW202118771A (zh) 2019-07-29 2020-07-28 疫苗
KR1020227006051A KR20220041144A (ko) 2019-07-29 2020-07-28 아프리카 돼지 열병 백신
PH1/2022/550063A PH12022550063A1 (en) 2019-07-29 2020-07-28 Vaccine
US17/628,286 US20220273788A1 (en) 2019-07-29 2020-07-28 Vaccine
CN202080062696.4A CN114375199A (zh) 2019-07-29 2020-07-28 非洲猪瘟疫苗
PCT/GB2020/051808 WO2021019232A1 (en) 2019-07-29 2020-07-28 African swine fever vaccine
AU2020322191A AU2020322191A1 (en) 2019-07-29 2020-07-28 African swine fever vaccine
MX2022001028A MX2022001028A (es) 2019-07-29 2020-07-28 Vacuna de la fiebre porcina africana.
BR112022000865A BR112022000865A2 (pt) 2019-07-29 2020-07-28 Vacina de peste suína africana
EP20751252.6A EP4003412A1 (en) 2019-07-29 2020-07-28 African swine fever vaccine
CL2022000161A CL2022000161A1 (es) 2019-07-29 2022-01-24 Vacuna contra la peste porcina africana
CONC2022/0001782A CO2022001782A2 (es) 2019-07-29 2022-02-21 Vacuna contra la peste porcina africana

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1910794.5A GB201910794D0 (en) 2019-07-29 2019-07-29 Vaccine

Publications (1)

Publication Number Publication Date
GB201910794D0 true GB201910794D0 (en) 2019-09-11

Family

ID=67990353

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1910794.5A Ceased GB201910794D0 (en) 2019-07-29 2019-07-29 Vaccine

Country Status (15)

Country Link
US (1) US20220273788A1 (https=)
EP (1) EP4003412A1 (https=)
JP (1) JP2022542174A (https=)
KR (1) KR20220041144A (https=)
CN (1) CN114375199A (https=)
AU (1) AU2020322191A1 (https=)
BR (1) BR112022000865A2 (https=)
CA (1) CA3148586A1 (https=)
CL (1) CL2022000161A1 (https=)
CO (1) CO2022001782A2 (https=)
GB (1) GB201910794D0 (https=)
MX (1) MX2022001028A (https=)
PH (1) PH12022550063A1 (https=)
TW (1) TW202118771A (https=)
WO (1) WO2021019232A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113373119A (zh) * 2021-06-02 2021-09-10 江西农业大学 一种表达非洲猪瘟病毒三基因缺失重组伪狂犬病毒毒株、构建方法及其应用
CN116444653B (zh) * 2023-03-09 2024-03-15 中国农业科学院上海兽医研究所(中国动物卫生与流行病学中心上海分中心) 一株阻断性非洲猪瘟病毒单克隆抗体杂交瘤细胞株的制备与应用
CN116284261B (zh) * 2023-04-04 2024-04-19 中国人民解放军军事科学院军事医学研究院 一种非洲猪瘟病毒结构蛋白组合物及其制备的疫苗

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU23544A1 (es) * 2006-02-28 2010-06-17 Ct Ingenieria Genetica Biotech Antígenos vacunales quiméricos contra el virus de la peste porcina clásica
ES2337113B1 (es) * 2007-04-17 2011-01-24 Centre De Recerca En Sanitat Animal (Cresa) Empleo de la hemaglutinina del virus de la peste porcina africana como adyuvante.
WO2009008888A1 (en) * 2007-07-10 2009-01-15 Matthias Rath African swine virus polypeptides as vaccines and its therapeutic use thereof
EP2202298A1 (en) * 2008-12-23 2010-06-30 Stichting Dienst Landbouwkundig Onderzoek Recombinant classical swine fever virus (CSFV) comprising a modified E2 protein and methods for generating said recombinant CSFV
WO2014005643A1 (en) * 2012-07-05 2014-01-09 Okairos Ag Novel prime-boosting regimens involving immunogenic polypeptides encoded by polynucleotides
GB201410971D0 (en) * 2014-06-19 2014-08-06 Pirbright Inst The Vaccine
WO2017096341A2 (en) * 2015-12-04 2017-06-08 The Texas A&M University System Adenovirus-vectored multivalent vaccine
RU2654586C2 (ru) * 2016-04-20 2018-05-21 Федеральное государственное бюджетное научное учреждение "Федеральный исследовательский центр вирусологии и микробиологии", (ФГБНУ ФИЦВиМ) Рекомбинационная кассета, содержащая гены EP153R и EP364R штамма Congo (КК-262) вируса африканской чумы свиней и рекомбинантный штамм ΔСongoCD2v вируса африканской чумы свиней
WO2021176235A1 (en) * 2020-03-06 2021-09-10 The Pirbright Institute Vaccine against african swine fever virus infection

Also Published As

Publication number Publication date
CN114375199A (zh) 2022-04-19
JP2022542174A (ja) 2022-09-29
MX2022001028A (es) 2022-02-23
AU2020322191A1 (en) 2022-03-03
EP4003412A1 (en) 2022-06-01
PH12022550063A1 (en) 2023-04-12
TW202118771A (zh) 2021-05-16
KR20220041144A (ko) 2022-03-31
BR112022000865A2 (pt) 2022-03-08
CL2022000161A1 (es) 2022-10-21
CO2022001782A2 (es) 2022-06-21
US20220273788A1 (en) 2022-09-01
WO2021019232A1 (en) 2021-02-04
CA3148586A1 (en) 2021-02-04

Similar Documents

Publication Publication Date Title
GB202010425D0 (en) Combination vaccine
GB202002166D0 (en) Vaccine
SG11202010821TA (en) Vaccine composition
IL292272A (en) Cancer vaccine
SG11202009147UA (en) Vaccine compositions
GB201910794D0 (en) Vaccine
GB201917699D0 (en) Vaccine conjugates
SG11202107203UA (en) Mrna vaccine
GB201811382D0 (en) Vaccine
EP4429699A4 (en) SARS-CoV-2 VACCINES
GB202112149D0 (en) Shigellla vaccine
GB201911636D0 (en) Vaccine
GB202016954D0 (en) Vaccine
GB202119115D0 (en) Vaccine
GB202118110D0 (en) Vaccine
GB202114274D0 (en) SARS-CoV-2 vaccine
GB202116831D0 (en) Vaccines
GB202102677D0 (en) Vaccine
GB202112499D0 (en) Beta-coronavirus vaccines
GB202109285D0 (en) Beta-coronavirus vaccines
GB202016165D0 (en) Vaccine
GB202014719D0 (en) Vaccine
GB202013534D0 (en) Vaccine
GB202013541D0 (en) Vaccine
GB202013253D0 (en) Vaccine

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)